-- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review -- -- Expect ...

As of November 9, 2025, the average one-year price target for Savara is $10.52/share. The forecasts range from a low of $7.07 to a high of $16.80. The average price target represents an increase of ...

As of November 9, 2025, the average one-year price target for Savara is $10.52/share. The forecasts range from a low of $7.07 to a high of $16.80. The average price target represents an increase of ...

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF ...

Investing.com - Citizens lowered its price target on Savara (NASDAQ:SVRA) to $10.00 from $11.00 on Thursday, while maintaining a Market Outperform rating on the stock. Currently trading at $4.12, ...

NEW YORK - October 23, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover ...

I’m exposing the TRUTH about outlet stores — GAP Outlet, Nike Factory Store, Old Navy Outlet, Nordstrom Rack, and more. If you think you’re getting designer brands for less… think again. We went ...

LOS ANGELES, Nov. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Company" ...

Oppenheimer raised the firm’s price target on Savara (SVRA) to $9 from $8 and keeps an Outperform rating on the shares. Ahead of December 2025 BLA submission for MOLBREEVI, the firm continues to see a ...

Journalists at The Associated Press utilize a set of standards and practices that safeguards AP stories from bias and inaccuracies. AP’s audio content always must be accurate. We do not alter or ...